Abstract 498P
Background
Frailty is of importance for older lung cancer patients, but the remaining lifetime is still not estimated for frailty but solely relied on cancer stage or cell type. In this study, we aimed to estimate survival and life expectancy of older non-small cell lung cancer patients (NSCLC) by frailty status, using electronic-health records.
Methods
We retrospectively analyzed 4260 patients aged between 65 and 95 who were newly diagnosed with NSCLC in 2007-2018 in National Cancer Center, Korea and followed up until December 2020. Frailty was measured by laboratory tests before initial treatment (FI-Lab), then classified into non-frail (score <0.25) and frail groups (score>0.25). Kaplan-Meier curves and log-rank test were used to compare survival probabilities by frailty. Cox proportional hazard model were used to estimate effect of frailty on all-cause mortality, adjusted for age, sex and SEER stage. We also estimate average life expectancy by frailty for all patients and stratified by SEER stage.
Results
There were 1063 (25%) patients identified as being frail. Frail patients had a significantly poorer survival than the non-frail in total population, and in SEER stage groups. Overall, frailty is significantly associated with all-cause mortality (aHR: 1.65, 95% CI: 1.52-1.78). Average life expectancies of frail older patients were 7.75 (95% CI 6.48-9.27) years for localized stage, 3.55 (95% CI 3.05-4.08) years for regional stage and 0.89 (95% CI 0.78-1.02) years for distant stage. While these figures for non-frail patients diagnosed in same cancer stage were 10.05 (95% CI 9.49-11.38), 4.99 (95% CI 4.67-5.32), 1.94 (95%CI 1.82-2.06) respectively.
Conclusions
Survival and life expectancy of older NSCLC patients vary by frailty status. In clinical settings, frailty can be simply assessed by laboratory tests to provide more precise estimates of remaining life-year and help oncologists to better plan for treatment decision and follow-up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Cancer Center Grant (No. NCC-2210880-2, NCC-2310450-1). In addition, one of the authors, Minh Thao Tu was supported by the “International Cooperation & Education Program” (NCCRI·NCCI 52210-52211, 2023)” of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract